Physiologically based toxicokinetic modelling as a tool to assess target organ toxicity in route-to-route extrapolation-The case of coumarin

Toxicology Letters

Volumn 202, Issue 2, 2011, Pages 100-110

  Mielke, Hans ^a   Abraham, Klaus ^a   Götz, Mario ^a   Vieth, Bärbel ^a   Lampen, Alfonso ^a   Luch, Andreas ^a   Gundert Remy, Ursula ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

Coumarin; Effect dose metric; Physiologically based toxicokinetic (PBTK) modelling; Risk assessment; Route to route extrapolation

Indexed keywords

COUMARIN;

ABSORPTION; AREA UNDER THE CURVE; ARTICLE; EXPOSURE; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; COMPUTER SIMULATION; COUMARINS; HUMANS; LIVER; MODELS, ANIMAL; RATS; RISK ASSESSMENT;

RATTUS;

EID: 79952627358     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.01.022     Document Type: Article

References (46)

1. Abraham K., Mielke H., Huisinga W., Gundert-Remy U. Elevated internal exposure of children in simulated acute inhalation of volatile organic compounds: effects of concentration and duration. Archives of Toxicology 2004, 79:63-73.
2. Abraham K., Wöhrlin F., Lindtner O., Heinemeyer G., Lampen A. Toxicology and risk assessment of coumarin: focus on human data. Molecular Nutrition & Food Research 2010, 54:228-239.
3. Api A.M. Lack of effect of coumarin on the formation of micronuclei in an in vivo mouse micronucleus assay. Food and Chemical Toxicology 2001, 39:837-841.
4. Andrejak M., Gerberg M., Sgro C., Decocq G., Hamel J.G., Monin M., Gras V. French pharmacovigilance survey evaluating the hepatic toxicity of coumarin. Pharmacoepidemiology and Drug Safety 1998, 7:45-50.
5. Beckley-Kartey S.A.J., Hotschkiss S.A.M., Capel M. Comparative in vitro skin absorption and metabolism of coumarin (1,2-benzopyrone) in human, rat, and mouse. Toxicology and Applied Pharmacology 1997, 145:34-42.
6. BfR (Bundesinstitut fuer Risikobewertung), 2006. Consumers, who eat a lot of cinnamon, currently have an overly high exposure to coumarin (BfR Nr. 043/2006). http://www.bfr.bund.de/cm/245/consumers_who_eat_a_lot_of_cinnamon_currently_have_an_overly_high_exposure_to_coumarin.pdf.
7. BfR (Bundesinstitut fuer Risikobewertung), 2007. Kosmetika können wesentlich zur Gesamtaufnahme von Cumarin beitragen. (BfR Nr. 049/2007). http://www.bfr.bund.de/cm/206/kosmetika_koennen_wesentlich_zur_gesamtaufnahme_von_cumarin_beitragen.pdf.
8. Born S.L., Api A.M., Ford R.A., Lefever F.R., Hawkins D.R. Comparative metabolism and kinetics of coumarin in mice and rats. Food and Chemical Toxicology 2003, 41:247-258.
9. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicology and Industrial Health 1997, 13:407-484.
10. Casley-Smith J.R. Benzo-pyrones in the treatment of lymphoedema. International Angiology 1999, 18:31-41.
11. Casley-Smith J.R., Morgan R.G., Piller N.B. Treatment of lymphedema of the arms and legs with 5,6 benzo-α-pyrone. New England Journal of Medicine 1993, 329:1158-1163.
12. Carlton B.D., Aubrun J.-C., Simon G.S. Effects of coumarin following perinatal and chronic exposure in Sprague-Dawley rats and CD1 mice. Fundamental and Applied Toxicology 1996, 30:145-151.
13. Cohen A.J. Critical review of the toxicology of coumarin with special references to interspecies difference in metabolism and hepatotoxic response and their significance to man. Food and Cosmetics Toxicology 1979, 17:277-289.
14. Edwards A.J., Price R.J., Renwick A.B., Lake B.G. Lack of effect of coumarin on unscheduled DNA synthesis in the in vivo rat hepatocyte DNA repair assay. Food and Chemical Toxicology 2000, 17:187-193.
15. EFSA (European Food Safety Authority) Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request from the commission related to coumarin. The EFSA Journal 2004, 104:1-136.
16. Evans M.V., Andersen M.E. Sensitivity analysis of a physiological model for 2,3,7,8-tatrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicological Sciences 2000, 54:71-80.
17. 14C]coumarin by rats and by human volunteers under simulated conditions of use in fragrances. Food and Chemical Toxicology 2001, 39:153-162.
18. Hagan E.C., Hansen W.H., Fitzhugh O.G., Jenner P.M., Jones W.I., Taylor J.M., Long E.L., Nelson A.A., Brouwer J.B. Food flavourings and compounds of related structure. II. Subacute and chronic toxicity. Food and Cosmetics Toxicology 1967, 12:141-157.
19. Hansch C., Hoekman D., Leo A., Zhang L., Li P. The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicology Letters 1995, 79:45-53.
20. Hazleton L.W., Tusing T.W., Zeithin B.R., Thiessen R., Murer H.K. Toxicity of coumarin. Journal of Pharmacology and Experimental Therapeutics 1956, 118:348-358.
21. HRC, 1983. Unpublished Report RNP 136/82493 Huntington Research Centre plc, Huntington, England (sponsored by Rhone-Poulenc) as cited by SCF (1997).
22. HRC, 1984. Unpublished Report RNP 137/83651 Huntington Research Centre plc, Huntington, England (sponsored by Rhone-Poulenc) as cited by SCF (1997).
23. Lake B.G. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food and Chemical Toxicology 1999, 37:423-453.
24. Lake B.G., Grasso P. Comparison of hepatotoxicity of coumarin in the rat, mouse, and Syrian hamster: a dose and time response study. Fundamental and Applied Toxicology 1996, 34:105-117.
25. Lake B.G., Evans J.G., Lewis D.F.V., Price R.J. Comparison of the hepatotoxic effects of coumarin, 3,4-dimethylcoumarin, dihydrocoumarin, and 6-methylcoumarin in the rat. Food and Chemical Toxicology 1994, 32:743-751.
26. Loprinzi C.L., Kugler J.W., Sloan J.A., Rooke T.W., Quella S.K., Novotny P., Mowat R.B., Michalak J.C., Stella P.J., Levitt R., Tschetter L.K., Windschitl H. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. New England Journal of Medicine 1999, 340:346-350.
27. National Toxicology Program (NTP), 1993. Toxicology and Carcinogenicity Studies of Coumarin (CAS no. 91-64-5) in F344/N rats and B6C3F mice. Technical Report Series No. 422, NIH Publication No. 93-3153. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
28. Pearce R., Greenway D., Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Archives of Biochemistry and Biophysics 1992, 298:211-225.
29. Ramsey J.C., Andersen M.E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicology and Applied Pharmacology 1984, 73:159-175.
30. Rietjens I.M.C.M., Boersma M.G., Zaleska M., Punt A. Differences in expected liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling. Toxicology In Vitro 2008, 22:1890-1901.
31. Ritschel W.A., Brady M.E., Tan H.S.I. First-pass effect of coumarin in man. International Journal of Clinical Pharmacology and Biopharmacy 1979, 17:99-103.
32. Ritschel W.A., Brady M.E., Tan H.S.I., Hoffmann K.A., Yiu I.M., Grummich K.W. Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. European Journal of Clinical Pharmacology 1977, 12:457-461.
33. Ritschel W.A., Hoffmann K.A., Tan H.S., Sanders P.R. Pharmacokinetics of coumarin upon i.v. administration in man. Arzneimittel-Forschung 1976, 26:1382-1387.
34. Ritschel W.A., Hussain S.A. Transdermal absorption and topical availability of coumarin. Methods and Findings in Experimental and Clinical Pharmacology 1988, 10:165-169.
35. Schmitt W. General approach for the calculation of tissue to plasma partition coefficient. Toxicology In Vitro 2008, 22:457-467.
36. Scientific Committee on Cosmetic Products, Non-Food Products intended for Consumers (SCCNFP) Opinion Concerning 6-Acetyl-1,1,2,4,4,7-Hexamethyltetryltetralin (AHTN) SCCNFP/0609/02 2002.
37. Scientific Committee on Cosmetic Products, Non-Food Products intended for Consumers (SCCNFP) Opinion Concerning 2002a. Opinion Concenrning Hexahydrohexamethyl-cyclopenta (γ)-2-benzopyran (HHCB) SCCNFP/0610/02 2002.
38. Scientific Committee on Cosmetic Products, Non-Food Products intended for Consumers (SCCNFP) Note for Guidance for Testing of Cosmetic Ingredients and their Safety Evaluation, 5th Revision 2003.
39. Scientific Committee on Cosmetic Products, Non-Food Products intended for Consumers (SCCNFP) Opinion Concerning Musk Xylene and Musk Keton, SCCNFP/0817/04 2004.
40. Scientific Committee on Consumer Products (SCCP) Note for Guidance for Testing of Cosmetic Ingredients and Their Safety Evaluation, 6th Revision 2006.
41. Scientific Committee on Food (SCF), 1997. Opinion on coumarin (a constituent of natural flavouring source materials limited by Annex II of flavourings directive 88/388/EEC), expressed on 16 December 1994. Reports of the Scientific Committee on Food (thirtysixth series). European Commission, Directorate General Industry. Luxembourg.
42. Scientific Committee on Food (SCF), 1999. Opinion on coumarin, expressed on 22/9/99. Available at: http://europa.eu.int/comm/food/fs/sc/scf/out40_en.pdf.
43. Schmeck-Lindenau H.J., Naser-Hijazi B., Becker E.W., Henneicke-van Zeppelin H.H., Schnitker J. Safety aspects of a coumarin-troxerutin combination regarding liver function in a double blind placebo controlled study. International Journal of Clinical Pharmacology and Therapeutics 2003, 41:193-199.
44. Swenberg, J.A., 2003. Covalent binding index study on coumarin. Report of laboratory of molecular carcinogenesis and mutagenesis, University of North Carolina, Chapel Hill, NC 27599, April 2003, USA. Submitted by European Flavour and Flagrance Association (EFFA), Square Marie-Louise, 49, B-1000 Brussels as cited by EFSA, 2004.
45. Umbach W. Kosmetik von Kopf bis Fuss 2004, Wiley-VCH Verlag, Weinheim, Germany. 3rd ed.
46. Yourick J.F., Bronaugh R.L. Percutaneous absorption and metabolism in human and rat skin. Journal of Applied Toxicology 1997, 17:153-158.